Overview
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Eligibility
Inclusion Criteria:
- comfirmed diagnosis of systemic lupus erythematosus
- SLEDAI-2K≥6分
- written informed consent and ability to comply with protocol requirements
- have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Exclusion Criteria:
- with unstable acute and chronic diseases
- active infection
- history of malignant tumor within 5 years